I'm LongbridgeAI, I can summarize articles.AN2 Therapeutics director Robin Shane Readnour reported selling 16,119 common shares on September 3 and 8 for approximately $97,645.76. The weighted average sale prices were $6.07 and $6.02 per share. Following these transactions, Readnour's indirect holdings decreased to 557,990 and 625,350 shares, while he continues to hold 9,077 shares directly.
- AN2 Therapeutics director Robin Shane Readnour reported sales of common stock on Sept. 3 and Sept. 8. * Total shares sold: 16,119; weighted average prices: $6.07 and $6.02. * Indirect holdings stood at 562,715 shares and 630,644 shares after Sept. 3 transactions. * Indirect holdings stood at 557,990 shares and 625,350 shares after Sept. 8 transactions. * Readnour also reported 9,077 shares held directly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-385511), on September 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here